S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Analysts boosted Snowflake stock, big firms are buying now
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Is CRISPR Therapeutics the NVIDIA of gene editing?
First it was Tyson stock, now this food company is set to rally
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
6 reasons to buy Teva Pharmaceuticals stock sooner than later
Block's multiple ecosystems drive shares higher on 2024 outlook
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Analysts boosted Snowflake stock, big firms are buying now
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Is CRISPR Therapeutics the NVIDIA of gene editing?
First it was Tyson stock, now this food company is set to rally
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
6 reasons to buy Teva Pharmaceuticals stock sooner than later
Block's multiple ecosystems drive shares higher on 2024 outlook
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Analysts boosted Snowflake stock, big firms are buying now
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Is CRISPR Therapeutics the NVIDIA of gene editing?
First it was Tyson stock, now this food company is set to rally
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
6 reasons to buy Teva Pharmaceuticals stock sooner than later
Block's multiple ecosystems drive shares higher on 2024 outlook
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Analysts boosted Snowflake stock, big firms are buying now
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Is CRISPR Therapeutics the NVIDIA of gene editing?
First it was Tyson stock, now this food company is set to rally
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
6 reasons to buy Teva Pharmaceuticals stock sooner than later
Block's multiple ecosystems drive shares higher on 2024 outlook

Standard BioTools (LAB) Earnings Date, Estimates & Call Transcripts

$2.45
+0.10 (+4.26%)
(As of 02/23/2024 08:53 PM ET)
Skip Charts & View Estimated and Actual Earnings Data

LAB Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

LAB Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

LAB Earnings Date and Information

Standard BioTools has confirmed that its next quarterly earnings report will be published on Wednesday, February 28th, 2024. Standard BioTools will be holding an earnings conference call on Wednesday, February 28th at 4:30 PM Eastern. Interested parties can register for or listen to the call..

Standard BioTools Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
2/28/2024
Confirmed)
-------  
11/7/2023Q3 2023-($0.19)($0.19)($0.11)$23.60 million$25.37 million
8/8/2023Q2 2023-($0.18)($0.18)($0.14)$24.20 million$27.67 million
5/9/2023Q1 2023-($0.14)($0.14)($0.07)-$25.12 million
2/14/2023Q4 2022-($0.21)($0.21)($0.16)-$27.02 million
11/8/2022Q3 2022-($0.32)($0.32)($0.27)-$25.65 million
8/8/2022Q2 2022-($0.39)($0.39)$0.04-$18.78 million
5/5/2022Q1 2022-($0.31)($0.31)$0.37-$26.50 million
2/17/2022Q4 2021-($0.06)($0.06)--$38.27 million
11/8/2021Q3 2021-($0.13)($0.13)($0.08)-$28.50 million
8/5/2021Q2 2021($0.15)($0.17)($0.02)($0.11)$30.93 million$31.02 million
5/6/2021Q1 2021($0.06)($0.20)($0.14)($0.15)$32.86 million$32.79 million












Standard BioTools Earnings - Frequently Asked Questions

When is Standard BioTools's earnings date?

Standard BioTools has confirmed that its next quarterly earnings data will be published on Wednesday, February 28th, 2024. Learn more on LAB's earnings history.

How much revenue does Standard BioTools generate each year?

Standard BioTools (NASDAQ:LAB) has a recorded annual revenue of $97.95 million.

How much profit does Standard BioTools generate each year?

Standard BioTools (NASDAQ:LAB) has a recorded net income of -$190.10 million. LAB has generated -$0.96 earnings per share over the last four quarters.


More Earnings Resources from MarketBeat

This page (NASDAQ:LAB) was last updated on 2/26/2024 by MarketBeat.com Staff